Patients with relapsed myeloma live longer on Kyprolis®** than on bortezomib**3

Kyprolis®** is the first next generation proteasome inhibitor to demonstrate in a randomised, phase III, relapsed multiple myeloma trial an overall survival benefit vs bortezomib** (median Overall Survival: Kd 47.6 months vs Vd 40.0 months, HR:0.79, P=0.01).3

** In combination with dexamethasone


  • Overall survival

    Click here for more information.

Please read the SmPC for full comprehensive safety information


  1. Stewart AK et al. N Engl J Med 2015;372:142–152.
  2. Dimopoulos MA et al. Lancet Oncol 2016;17:27–38.
  3. Dimopoulos MA et al. Abstract presented at the 16th International Myeloma Workshop; March 1–4, 2017; New Delhi, India.

Terms of Use

The information contained in this site is for European healthcare professionals only.